Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPSAB1 | Q15661 | 9/20 | 0.46 |
| ▸ | TPSD1 | Q9BZJ3 | 9/20 | 0.46 |
| ▸ | TPSG1 | Q9NRR2 | 9/20 | 0.46 |
| ▸ | F2 | P00734 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL904522 | 0.83 | EPHX1 (0.44) | CYP19A1CYP2C9 | |
| SCHEMBL904431 | 0.82 | CYP19A1 (0.43) | CYP19A1CYP2C9GRIN2B | |
| SCHEMBL27928038 | 0.79 | MAPT (0.50) | CYP19A1 | |
| SCHEMBL904456 | 0.79 | TPSAB1 (0.48) | TPSAB1TPSD1TPSG1F2PRSS1 | |
| SCHEMBL904540 | 0.71 | PTGIR (0.48) | CYP2C9GRIN2B | |
| SCHEMBL8396874 | 0.71 | TPSAB1 (0.55) | TPSAB1TPSD1TPSG1EPHX2CNR1 | |
| SCHEMBL904629 | 0.70 | CYP19A1 (0.40) | TPSAB1TPSD1TPSG1PRSS1CYP19A1 | |
| SCHEMBL904583 | 0.69 | CYP19A1 (0.38) | TPSAB1TPSD1TPSG1PRSS1CYP19A1 | |
| SCHEMBL904548 | 0.69 | NOS1 (0.39) | GRIN2B | |
| SCHEMBL8392252 | 0.69 | TPSAB1 (0.54) | TPSAB1TPSD1TPSG1EPHX2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621899-B1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-10-21 | — | — | EP | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| EP-2621899-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044046-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | OPRK1, OPRM1, OPRL1 | TPSAB1 2943/4885TPSD1 3074/4885TPSG1 4178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.